X0708 D LIVE 0001544227 Tempest Therapeutics, Inc. 2000 SIERRA POINT PARKWAY, SUITE 400 BRISBANE CA CALIFORNIA 94005 415-798-8589 DELAWARE None Millendo Therapeutics, Inc. OvaScience, Inc. Corporation true Matthew Angel Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Executive Officer Director President and Chief Executive Officer Constance Ames Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Executive Officer Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary John David Yee Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Director William Drake Richey Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Director Nancy Freda-Smith Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Director John Wilbert Frederick Tempest Therapeutics, Inc. 2000 Sierra Point Parkway, Suite 400 Brisbane CA CALIFORNIA 94005 Director Biotechnology Decline to Disclose 06b false 2026-09-15 true true true true Pre-funded warrants and Series C and Series D Common Stock Purchase Warrants, including underlying shares of common stock. false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 Park Avenue 3rd Floor New York NY NEW YORK 10022 NY NEW YORK false 7500000 7500000 0 Offering of 3,105,591 pre-funded warrants and accompanying 3,105,591 Series C and 3,105,591 Series D warrants, including the common stock underlying such warrants at combined exercise price of $0.804. Total offering amount excludes PA warrants (Item 15). false 1 225000 0 Includes a cash placement fee equal to 7.0% of the gross proceeds of the offering, reimbursement of $50,000 legal fees and warrants, exercisable upon stockholder approval, to purchase 217,391 common stock at an exercise price of $1.0063 per share. 0 false Tempest Therapeutics, Inc. /s/ Matthew Angel Matthew Angel President and Chief Executive Officer 2026-10-13